Karyopharm Therapeutics, Inc.
(NASDAQ : KPTI)

( )
KPTI After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.29%80.010.9%$589.41m
CELGCelgene Corporation
-1.22%137.171.1%$556.07m
AMGNAmgen Inc.
0.05%186.281.1%$452.39m
BIIBBiogen Inc.
0.03%344.581.2%$391.35m
REGNRegeneron Pharmaceuticals, Inc.
-0.72%439.372.7%$313.54m
ALNYAlnylam Pharmaceuticals, Inc
-0.97%117.5510.7%$253.20m
VRTXVertex Pharmaceuticals Incorporated
-0.12%154.861.9%$219.44m
INCYIncyte Corporation
-0.43%115.142.5%$206.28m
ALXNAlexion Pharmaceuticals, Inc.
-2.04%140.241.9%$178.91m
ILMNIllumina, Inc.
-0.42%205.623.5%$138.87m
EXELExelixis, Inc.
-2.72%27.536.5%$135.05m
BLUEBluebird Bio, Inc.
-0.79%139.1017.3%$114.78m
BMRNBioMarin Pharmaceutical Inc.
-5.26%88.624.4%$108.97m
CLVSClovis Oncology, Inc.
-3.20%78.7216.5%$108.85m
SRPTSarepta Therapeutics, Inc.
-0.58%51.4216.9%$107.58m

Company Profile

Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company, which discovers, develops, and commercializes drugs to treat cancer and other major diseases. The company intends to initiate a pivotal randomized Phase 3 study of selinexor in combination with bortezomib (Velcade) and low-dose dexamethasone (BOSTON) in patients with multiple myeloma. Karyopharm Therapeutics was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.